|
Most de-novo CML patients achieve good responses to imatinib, but the rate
and degree of molecular response is variable. We assessed the IC50(imatinib) in
62 de-novo chronic phase CML patients as a predictor of molecular response.
IC50(imatinib) was determined in pre therapy blood samples by measuring the
in-vitro imatinib-induced reduction of the phosphorylated form of the adaptor
protein Crkl.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
